Almost Half of the Dupilumab‐Treated Patients With Severe Chronic Rhinosinusitis With Nasal Polyps Achieve Remission in One Year
Authors:
- Josje J OttenJosje J Otten
- Hester E ElzingaHester E Elzinga
- Wytske J FokkensWytske J Fokkens
- Sietze ReitsmaSietze Reitsma
- PolyREG ConsortiumPCPolyREG Consortium
Open Access
Abstract
No abstract availableKeywords
Funding Information
- GlaxoSmithKline España
- Sanofi
- Novartis
This publication has 6 references indexed in Scilit:
- Steroid responsiveness predicts olfactory function recovery in dupilumab treated CRSwNP2024
- EPOS2020/EUFOREA expert opinion on defining disease states and therapeutic goals in CRSwNPRhinology journal, 2024
- Two‐year results of tapered dupilumab for CRSwNP demonstrates enduring efficacy established in the first 6 monthsAllergy, 2023
- Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): A multicentric observational Phase IV real‐life study (DUPIREAL)Allergy, 2023
- Respiratory epithelial adenomatoid hamartoma with nasal polyps affects dupilumab efficacyRhinology journal, 2022
- Real‐life observational cohort verifies high efficacy of dupilumab for chronic rhinosinusitis with nasal polypsAllergy, 2021